Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

COR · Q1 2026 Earnings

Cencora

Reported February 4, 2026

30-second summary

30-second take: Cencora opened FY26 with revenue of $85.9B (+5.5% YoY) and adjusted EPS of $4.08, and used the print to raise FY26 U.S. Healthcare Solutions operating income growth to 14–16% (from 9–11%) and consolidated adjusted OI growth to 11.5–13.5% (from 8–10%). Q1 revenue growth of 5.5% prints below the new 7–9% FY range; management expects acceleration as the oncology customer headwind dissipates by Q4. The catch: adjusted EPS guidance was reaffirmed at $17.45–$17.75 despite the operating raise, because net interest expense guidance jumped to $480–$500M (from $315–$335M) to fund the One Oncology acquisition and share count drifted up to 195.5M. Management has effectively converted the operational upside into M&A capacity rather than EPS accretion.

Headline numbers

EPS

Q1 FY2026

$4.08

Revenue

Q1 FY2026

$85.90B

+5.5% YoY

Gross margin

Q1 FY2026

3.6%

Operating margin

Q1 FY2026

0.9%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$85.90B	+5.5%	$83.70B	+2.6%
EPS	$4.08	—	$3.84	+6.3%
Gross margin	3.6%	—	3.5%	+5bps
Operating margin	0.9%	—	0.0%	+86bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2026	5% to 7% growth	7% to 9% growth	+2 percentage points at both low and high end	Raised
Adjusted Operating Income Growth	FY 2026	8% to 10% growth	11.5% to 13.5% growth	+3.5 percentage points at low end, +3.5 percentage points at high end	Raised
U.S. Healthcare Solutions Segment Revenue Growth	FY 2026	5% to 7% growth	7% to 9% growth	+2 percentage points at both low and high end	Raised
U.S. Healthcare Solutions Segment Operating Income Growth	FY 2026	9% to 11% growth	14% to 16% growth	+5 percentage points at both low and high end	Raised
International Healthcare Solutions Segment Revenue Growth	FY 2026	6% to 8% growth	7% to 9% growth	+1 percentage point at both low and high end	Raised
Other Segment Revenue Growth	FY 2026	0% to 4% growth	1% to 5% growth	+1 percentage point at both low and high end	Raised
Other Segment Operating Income Growth	FY 2026	1% to 4% decline	Flat	From -1% to -4% decline midpoint to 0% midpoint; approximately +2-4 percentage points	Raised
Net Interest Expense	FY 2026	$315M to $335M	$480M to $500M	+$145M to +$165M (approximately +46-49%)	Raised
Adjusted Effective Tax Rate	FY 2026	20% to 21%	~20%	Narrowed and lowered to point estimate of 20% (bottom of prior range)	Lowered
Diluted Weighted Average Shares Outstanding	FY 2026	~194M	195.5M	+1.5M shares (+0.8%)	Raised

Reaffirmed unchanged this quarter: Adjusted Diluted EPS ($17.45 to $17.75), International Healthcare Solutions Segment Operating Income Growth (5% to 8% growth)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
U.S. Healthcare Solutions	$76.2B	+5.0%
International Healthcare Solutions	$7.6B	+9.6%
Other	$2.1B	+6.3%
U.S. Healthcare Solutions Operating Income	$831M	—
U.S. Healthcare Solutions Operating Margin	1.09%	—
International Healthcare Solutions Operating Income	$142M	—
International Healthcare Solutions Operating Margin	1.86%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Adjusted Operating Income	$1,063M
Adjusted Operating Margin	1.24%

Management tone

Customer optimization hangover → U.S. specialty acceleration → MSO platform deepening → Portfolio pruning and capacity commitment → MSO as the operating identity.

Two quarters ago One Oncology was a "pathway to full ownership"; last quarter it was templated as EPS-neutral; this quarter it has closed and is the explicit driver of the largest mid-year operating income guidance raise this company has issued in recent memory. The anchor: "we are pleased to now be reaffirming our full guidance range of $17.45 to $17.75 to reflect our strong execution, the continued performance of our U.S. healthcare solutions segment, and the expected contribution from One Oncology." The shift is that One Oncology has moved from a strategic option to a quantified operating contributor in a single quarter, and management is signaling that the MSO platform now has two market-leading anchors (RCA + One Oncology) capable of cross-platform capability sharing.

MSOs have stopped being framed as acquisitions and are now being framed as the natural extension of the core specialty business. A quarter ago RCA was a "successful acquisition…going really well"; this quarter Bob Mauch said "Our investments in pharmaceutical-centric MSOs represent a natural extension of our longstanding leadership in specialty pharmaceuticals, complementing our existing specialty distribution and GPO services." The semantic shift matters because it positions future MSO investment as organic expansion rather than M&A risk — and it pre-empts the question of whether the FY26 raise is acquisition-driven or operationally durable.

Management is preemptively defending the underlying organic growth rate against the inevitable "you only beat because of M&A" critique. "If you back out RCA and exclude one oncology, we're still solidly within that long-term guidance range of seven to 10%…even when you X out things like RCA and one oncology, we're performing solidly within that long-term guidance range that we've increased a couple times in the last few months." This is the same defensive framing that appeared in Q3 FY25 around GLP-1 contribution — getting ahead of the bear case before it forms.

The portfolio refocus narrative is now backed by tangible operating actions. Management disclosed the full impairment of depreciable assets in the U.S. consulting business as of December 31, 2025 — Jim Cleary noted "we are pleased that we are making progress on focusing our portfolio." Combined with the Other segment OI inflecting to flat in the new guide (driven by the elimination of future depreciation expense on those impaired assets), the divestiture process appears to be advancing on the ground even before any transaction has been announced.

The reaffirmed EPS range despite a 350bps OI raise is being handled with unusual transparency rather than spin. Management did not pretend the interest expense increase wasn't material — they quantified it ($480–$500M from $315–$335M) and tied it directly to One Oncology financing. This is the language of a company confident enough in operational momentum to absorb a $165M headline interest expense headwind without flinching.

Recurring themes management leaned on this quarter:

MSO platform expansion as competitive moat and specialty pharmaceutical growth driverStrength in specialty pharmaceuticals and health systems partnerships offsetting customer lossesGLP-1 utilization trends and adoption momentum continuing at scaleOperating leverage and margin expansion despite pharmaceutical price pressuresInternational recovery tied to timing dynamics with specialty logistics momentumStrategic portfolio refocus toward growth-oriented investments

Risks management surfaced:

Loss of oncology customer acquired by competitor (headwind through Q3)Timing-dependent manufacturer price adjustments in developing markets affecting international segmentIncreased interest expense burden from One Oncology acquisition debt ($480-500M vs prior $315-335M guidance)Paused share repurchases constraining near-term EPS accretion despite strong operational performancePotential dilution from strategic divestitures in near term, though viewed as long-term growth positive

Answers to last quarter's watch list

Q1 FY26 U.S. HC Solutions OI growth — within the 9–11% FY band despite the oncology customer headwind? Yes, and then some. Q1 U.S. HC Solutions OI of $831M came in strong enough that management raised the full-year U.S. OI growth guide by 500bps to 14–16%. Management explicitly said the core business excluding RCA and One Oncology is still at the higher end of the 7–10% long-term range, meaning RCA, One Oncology, and operating execution are stacking.

Resolved positively

Pace and structure of divestitures for MWI, U.S. hub services, Profarma, and PharmaLex components — any completed transactions in Q1? No transactions announced this quarter, but the full impairment of depreciable assets in the U.S. consulting business signals active portfolio cleanup. The Other segment OI guide inflecting from -1 to -4% decline to "flat" reflects the elimination of future depreciation on those impaired assets.

Continue monitoring

International HC Solutions OI inflection actually printing positive in Q1 FY26? Partially. Int'l revenue grew 9.6% YoY (above the new 7–9% as-reported FY guide) and segment OI of $142M generated a 1.86% margin — well above recent run-rate. Management attributed segment OI weakness in European distribution to "timing of manufacturer price adjustments in a developing market country" and templated recovery through FY26. The Int'l OI growth guide was reaffirmed at 5–8% despite revenue upside, implying the inflection is on track but not yet decisive.

Continue monitoring

One Oncology path-to-full-ownership disclosure — structure, timing, cost? Resolved. The acquisition has closed and is now contributing to FY26 guidance, with management reaffirming it will be "neutral net of financing costs to adjusted diluted EPS in its first 12 months." The $145–$165M increase in net interest expense guidance is the implicit financing cost disclosure. Share repurchases have been paused to support the deal financing. Status: Resolved positively (deal done, contribution quantified).

$1B distribution capacity commitment showing up in Q1 capex run rate? Capex guidance reaffirmed at ~$900M for FY26, unchanged from last quarter's guide. The $1B-through-2030 envelope appears to be phasing in within the existing capex envelope rather than driving it higher. Status: Resolved positively (no negative surprise).

What to watch into next quarter

Q2 FY26 U.S. HC Solutions OI growth — Q1 already drove a 500bps full-year raise; watch whether Q2 confirms the 14–16% trajectory or shows the oncology customer headwind still weighing on the print before it dissipates in Q4.

First announced divestiture transaction from the Other segment (MWI, U.S. hub services, Profarma, PharmaLex components) — the FY26 Other segment OI guide inflecting to flat already embeds expectations, so the structure and proceeds of the first deal will calibrate the value-creation thesis.

Whether Int'l HC Solutions OI growth actually prints inside the 5–8% reaffirmed FY range in Q2 — segment OI margin of 1.86% in Q1 is a strong starting point, but the European timing recovery management flagged is the variable.

Capital allocation framework once share repurchases resume — management paused buybacks for One Oncology; the timing of resumption signals confidence in leverage and free cash flow conversion.

Any MSO platform consolidation signals — with two market-leading MSO anchors now in place, watch for either bolt-on MSO acquisitions or explicit capability-sharing disclosures (e.g. RCA clinical trial capabilities deployed into One Oncology).

Sources

Cencora Q1 FY2026 press release (Exhibit 99.1, filed 2026-02-04): https://www.sec.gov/Archives/edgar/data/1140859/000114085926000004/exhibit991-q12026.htm
Cencora Q1 FY2026 earnings call prepared remarks (as extracted)
Cencora Q4 FY2025 brief (Tapebrief, 2025-11-05) for prior-guide reference points
Cencora Q3 FY2025 brief (Tapebrief, 2025-08-06) for multi-quarter tone context

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.